Inflammatory bowel disease is a progressive and debilitating condition. Early and effective
treatment utilizing a treat to target approach is key in improving patient outcomes. Therefore …

Background & Aims Clinical remission, defined by a composite of patient reported outcomes
and Mayo endoscopy subscore (MES) 0 or 1 is a recommended treatment target in patients …

Currently, the main targets of drug therapy for ulcerative colitis [UC] are endoscopic and
clinical remission. However, there is active discussion about the additional advantages of …

Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients
with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are …

The term IBD is usually used for referring to a group of inflammatory gastro-intestinal
diseases (mainly Crohn's disease and ulcerative colitis). Accordingly, IBD arises as a result …

Inflammatory bowel disease (IBD) denotes a group of chronic incurable disorders
characterized by relapsing-remitting inflammation of the gastrointestinal tract. IBD represents …

Abstract Leucine-rich alpha-2 glycoprotein (LRG) may be a novel serum biomarker for
patients with inflammatory bowel disease. The association of LRG with the endoscopic …

Background: Inflammatory bowel disease (IBD) is a chronically relapsing disease with a
continuous need for proactive monitoring to decide appropriate treatments and follow-up …

Background & Aims The effect of pregnancy on inflammatory bowel disease (IBD) remains
poorly understood. We aimed to monitor intestinal inflammation using fecal calprotectin (FC) …

The number of patients with inflammatory bowel disease (IBD) is increasing worldwide.
Endoscopy is the gold standard to assess the condition of IBD. The problem with this …